AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7817456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extracts or intravesical antineoplastic iontophoresis
Number of subjects: 0
Study 2918185 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and enprofylline
Number of subjects: 29
Study 2918185 — intervention group
Group type: COMPARATOR
Intervention: Antigen
Number of subjects: 29
Study 2918185 — intervention group
Group type: COMPARATOR
Intervention: Compound 48/80
Number of subjects: 29
Study 2918185 — intervention group
Group type: COMPARATOR
Intervention: Antigen vs Compound 48/80
Number of subjects: 29
Study 803187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine/nortriptyline (F/N)
Number of subjects: 72
Study 803187 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 72
Study 29106053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosdagrocorat (PF-04171327)
Number of subjects: 0
Study 29106053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29106053 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 0
Study 28699563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clusters (CASCADA intervention)
Number of subjects: 6185
Study 28699563 — intervention group
Group type: EXPERIMENTAL
Intervention: Female intervention responses
Number of subjects: 6185
Study 28699563 — intervention group
Group type: EXPERIMENTAL
Intervention: Male intervention responses
Number of subjects: 6185
Study 28699563 — intervention group
Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 6185
Study 28699563 — intervention group
Group type: COMPARATOR
Intervention: Female control respondents
Number of subjects: 6185
Study 28699563 — intervention group
Group type: COMPARATOR
Intervention: Male control respondents
Number of subjects: 6185
Study 26143444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) plus peginterferon alfa‐2a (PegIFN) for 48 weeks
Number of subjects: 737
Study 26143444 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF plus PegIFN for 16 weeks followed by TDF for 32 weeks
Number of subjects: 737
Study 26143444 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFN for 48 weeks
Number of subjects: 737
Study 26143444 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF for 120 weeks
Number of subjects: 737
Study 26143444 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 737
Study 23269313 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary stenting
Number of subjects: 164
Study 20844893 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic sphincterotomy followed by laparoscopic cholecystectomy (PES/LC)
Number of subjects: 198
Study 20844893 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy combined with intraoperative endoscopic sphincterotomy (LC/IOES)
Number of subjects: 198
Study 20844893 — intervention group
Group type: COMPARATOR
Intervention: Control group (PES/LC)
Number of subjects: 198
Study 18720890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained volunteer-delivered mental health support
Number of subjects: 102
Study 18720890 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 102
Study 17361529 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Western medicine plus Xin'anning Nasal Drop (XAND)
Number of subjects: 60
Study 17361529 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 60
Study 12598392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received videotapes and a brochure designed to review skills for self control and treatment
Number of subjects: 332
Study 12598392 — intervention group
Group type: COMPARATOR
Intervention: Control group received a videotape and brochure with general diabetes information
Number of subjects: 332
Study 12598392 — intervention group
Group type: COMPARATOR
Intervention: Control group received traditional treatment only
Number of subjects: 332
Study 10538257 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening CT scans within 24 hours of admission
Number of subjects: 22
Study 10538257 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT studies at physician's discretion)
Number of subjects: 22
Study 8671551 — intervention group
Group type: EXPERIMENTAL
Intervention: Espresso (E)
Number of subjects: 84
Study 8671551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mocha (M)
Number of subjects: 84
Study 8671551 — intervention group
Group type: COMPARATOR
Intervention: Tea (T)
Number of subjects: 84
Study 1817621 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cm H2O CPAP via a nasal mask
Number of subjects: 150
Study 1817621 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 cm H2O CPAP via a nasal mask
Number of subjects: 150
Study 1817621 — intervention group
Group type: COMPARATOR
Intervention: 0 cm H2O CPAP (Control)
Number of subjects: 150
Study 7040657 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline flush following diazepam administration
Number of subjects: 500
Study 7040657 — intervention group
Group type: COMPARATOR
Intervention: Barbotage (diluting the drug with the patient's own blood before injection)
Number of subjects: 500
Study 31035117 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel (8%, 90 mg) once daily
Number of subjects: 1313
Study 31035117 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (progesterone oil) once daily
Number of subjects: 1313
Study 31035117 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Number of subjects: 1313
Study 31035117 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone
Number of subjects: 1313
Study 31035117 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel and Intramuscular progesterone
Number of subjects: 1313
Study 28114711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 57
Study 28114711 — intervention group
Group type: COMPARATOR
Intervention: Control Group (KG)
Number of subjects: 57
Study 26505104 — intervention group
Group type: EXPERIMENTAL
Intervention: science-causal explanations (SC)
Number of subjects: 94
Study 26505104 — intervention group
Group type: EXPERIMENTAL
Intervention: clinical concepts before basic science (CB)
Number of subjects: 94
Study 26505104 — intervention group
Group type: EXPERIMENTAL
Intervention: clinical features list only (FL)
Number of subjects: 94
Study 26505104 — intervention group
Group type: EXPERIMENTAL
Intervention: basic science before clinical concepts (BC)
Number of subjects: 94
Study 23830936 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly resistance training (1x RT)
Number of subjects: 155
Study 23830936 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training (2x RT)
Number of subjects: 155
Study 23830936 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly balance and tone training (BAT)
Number of subjects: 155
Study 22137075 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d) with cilostazol (200 mg/d) for 14 days (group 3)
Number of subjects: 74
Study 22137075 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d) for 14 days (group 1)
Number of subjects: 74
Study 22137075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-maintenance dose of clopidogrel (150 mg/d) for 14 days (group 2)
Number of subjects: 74
Study 22137075 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d) for 14 days (control group)
Number of subjects: 74
Study 19232828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 42
Study 17971943 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg/d for 48 weeks
Number of subjects: 210
Study 17971943 — intervention group
Group type: COMPARATOR
Intervention: Diammonium glycyrrhizinate
Number of subjects: 210
Study 17971943 — intervention group
Group type: COMPARATOR
Intervention: Diammonium glycyrrhizinate alone
Number of subjects: 210
Study 15006963 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-breath DLNO measurements (inspired nitric oxide concentration, 66.5 ± 10.6 ppm)
Number of subjects: 8
Study 15006963 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-breath DLNO measurements at rest and at 90% VO(2)R
Number of subjects: 8
Study 15006963 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise regression analysis of DLNO
Number of subjects: 8
Study 11791956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) 25 mg/kg
Number of subjects: 0
Study 11791956 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ) 15 mg/kg
Number of subjects: 0
Study 10930676 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine
Number of subjects: 31
Study 10930676 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjuvanted subunit influenza vaccine
Number of subjects: 31
Study 10930676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9065352 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (256 micrograms/day)
Number of subjects: 318
Study 9065352 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (400 micrograms/day)
Number of subjects: 318
Study 9065352 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide pMDI (400 micrograms/day)
Number of subjects: 318
Study 9065352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 8417382 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 106
Study 8417382 — intervention group
Group type: COMPARATOR
Intervention: No calcium-channel blocker
Number of subjects: 106
Study 3786479 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine
Number of subjects: 0
Study 3786479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30055891 — intervention group
Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy without impaction
Number of subjects: 20
Study 30055891 — intervention group
Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy with impaction
Number of subjects: 20
Study 29926695 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 120 seconds after birth
Number of subjects: 100
Study 29926695 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 100
Study 29926695 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) and Immediate cord clamping (ICC)
Number of subjects: 100
Study 24530676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 4432
Study 22228743 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) 600 mg once daily for 5 weeks
Number of subjects: 51
Study 22228743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 20337981 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding starting within 24 hours of birth
Number of subjects: 0
Study 20337981 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20337981 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 0
Study 18704871 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme provided by a specifically trained psychologist, including individualized units and group lectures.
Number of subjects: 140
Study 18704871 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme measured ten days after CABG surgery.
Number of subjects: 140
Study 18704871 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual care, n=70.
Number of subjects: 140
Study 15685250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 1336
Study 15685250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1336
Study 14593034 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-commercial funding support for randomised controlled trials
Number of subjects: 1464
Study 14593034 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug trials
Number of subjects: 1464
Study 14593034 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS research and development programme
Number of subjects: 1464
Study 14593034 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Research Council and medical research charities
Number of subjects: 1464
Study 10487503 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg daily for 12 weeks)
Number of subjects: 12
Study 9097708 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA expression in CIN patients
Number of subjects: 156
Study 1924776 — intervention group
Group type: EXPERIMENTAL
Intervention: Puncture-site-down positioning (n = 36)
Number of subjects: 55
Study 1924776 — intervention group
Group type: COMPARATOR
Intervention: Puncture-site-up positioning (n = 19)
Number of subjects: 55
Study 30236238 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 4 mg kg‐1
Number of subjects: 448
Study 30236238 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 16 mg kg‐1
Number of subjects: 448
Study 30236238 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 448
Study 27786344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity (TPA)
Number of subjects: 141
Study 27786344 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self-Management Program (CPSMP)
Number of subjects: 141
Study 27786344 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 141
Study 24874474 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT) with high AEG-1 expression
Number of subjects: 158
Study 24874474 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulation of AEG-1 in colon cancer cell lines
Number of subjects: 158
Study 24874474 — intervention group
Group type: COMPARATOR
Intervention: Normal mucosa
Number of subjects: 158
Study 21769733 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-10 Numeric Rating Scale (NRS)
Number of subjects: 33
Study 21266736 — intervention group
Group type: EXPERIMENTAL
Intervention: Live High:Train Low (LHTL, n = 6)
Number of subjects: 17
Study 21266736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 17
Study 21266736 — intervention group
Group type: COMPARATOR
Intervention: Nocebo (n = 5)
Number of subjects: 17
Study 18725113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated whole-breast irradiation
Number of subjects: 0
Study 18725113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated partial-breast irradiation
Number of subjects: 0
Study 18725113 — intervention group
Group type: COMPARATOR
Intervention: Conventional whole-breast irradiation
Number of subjects: 0
Study 16624882 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.15 mg/kg
Number of subjects: 133
Study 16624882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg
Number of subjects: 133
Study 12728539 — intervention group
Group type: EXPERIMENTAL
Intervention: troglitazone 200 mg/day
Number of subjects: 137
Study 12728539 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 137
Study 10884075 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 36
Study 10884075 — intervention group
Group type: COMPARATOR
Intervention: Short-incision open carpal tunnel release
Number of subjects: 36
Study 8741948 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol pretreatment (0.5 g/kg and 1.0 g/kg)
Number of subjects: 11
Study 8741948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no alcohol)
Number of subjects: 11
Study 8741948 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reinforcement (varying amounts of money)
Number of subjects: 11
Study 8741948 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-analog ratings (good effects)
Number of subjects: 11
Study 8741948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output across all alcohol and monetary conditions
Number of subjects: 11
Study 1414040 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg methotrexate (MTX) administered intramuscularly once a week
Number of subjects: 102
Study 1414040 — intervention group
Group type: COMPARATOR
Intervention: 50 mg gold sodium thiomalate (GST) administered intramuscularly once a week
Number of subjects: 102
Study 1414040 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg methotrexate (MTX)
Number of subjects: 102
Study 1414040 — intervention group
Group type: COMPARATOR
Intervention: 50 mg gold sodium thiomalate (GST)
Number of subjects: 102
Study 2580179 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg + hydrochlorothiazide (HCTZ) 25 mg twice a day
Number of subjects: 55
Study 2580179 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 55
Study 2580179 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose captopril (3 X 50-3 X 150 mg, mean = 325 +/- 87 mg/day) changed to low-dose captopril (2 X 50 mg, mean = 96 +/- 14 mg/day) in a fixed combination with 25 mg HCTZ
Number of subjects: 55
Study 30569654 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy incidental state priming
Number of subjects: 0
Study 30569654 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearful incidental state priming
Number of subjects: 0
Study 30569654 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral incidental state priming
Number of subjects: 0
Study 29726361 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate (MF) cream applied twice daily from day 1 of PMRT to 14 days after PMRT
Number of subjects: 124
Study 29726361 — intervention group
Group type: COMPARATOR
Intervention: Eucerin Original (E) cream applied twice daily from day 1 of PMRT to 14 days after PMRT
Number of subjects: 124
Study 29726361 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate (MF) cream
Number of subjects: 124
Study 29726361 — intervention group
Group type: COMPARATOR
Intervention: Eucerin Original (E) cream
Number of subjects: 124
Study 29726361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 124
Study 26777097 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronectomy with guided bony regeneration
Number of subjects: 6
Study 26777097 — intervention group
Group type: COMPARATOR
Intervention: Coronectomy alone (Control)
Number of subjects: 6
Study 24932565 — intervention group
Group type: EXPERIMENTAL
Intervention: Marriage Checkup (MC) treatment
Number of subjects: 215
Study 24932565 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 215
Study 22360430 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose solution
Number of subjects: 2
Study 22360430 — intervention group
Group type: COMPARATOR
Intervention: Amino acids mixture (F-group)
Number of subjects: 2
Study 19941285 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling program (16 sessions over one year)
Number of subjects: 304
Study 19941285 — intervention group
Group type: COMPARATOR
Intervention: Resource directory for breast cancer (control group)
Number of subjects: 304
Study 17641484 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided pathfinding assistance
Number of subjects: 87
Study 17641484 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 87
Study 16092310 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01mg/kg
Number of subjects: 90
Study 16092310 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate 0.005mg/kg
Number of subjects: 90
Study 12142117 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30
Study 12142117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 30
Study 12142117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10453872 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone for 3 months (20 mg/d for 8 weeks, 15 mg/d for 2 weeks, and 10 mg/d for 2 weeks) followed by inhaled budesonide (800 microg bid for 15 months)
Number of subjects: 189
Study 10453872 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets followed by placebo inhaler therapy
Number of subjects: 189
Study 7565828 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A
Number of subjects: 10
Study 7565828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2334037 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 ml/kg of Ringer's acetate solution immediately before spinal anaesthesia (Group A)
Number of subjects: 60
Study 2334037 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 ml/kg of Ringer's acetate solution immediately before spinal anaesthesia (Group B)
Number of subjects: 60
Study 2334037 — intervention group
Group type: COMPARATOR
Intervention: No volume preload (Group C)
Number of subjects: 60
Study 2334037 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature sensation blocked to T7 and above (n = 25)
Number of subjects: 60
Study 2334037 — intervention group
Group type: EXPERIMENTAL
Intervention: Block height above T7
Number of subjects: 60
Study 498720 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking MH containing 7.5 mg (‐) delta‐9‐tetrahydrocannabinol
Number of subjects: 6
Study 498720 — intervention group
Group type: COMPARATOR
Intervention: Placebo marihuana (PL)
Number of subjects: 6
Study 498720 — intervention group
Group type: COMPARATOR
Intervention: Control (not smoking)
Number of subjects: 6
Study 31828315 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete substitution of cigarettes with e‐cigarettes (CS‐E)
Number of subjects: 264
Study 31828315 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete substitution of cigarettes with nicotine gum or lozenge (CS‐NRT)
Number of subjects: 264
Study 31828315 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum use of e‐cigarettes (AD‐E)
Number of subjects: 264
Study 31828315 — intervention group
Group type: COMPARATOR
Intervention: Continue smoking of usual brand cigarettes (UB)
Number of subjects: 264
Study 31550872 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and ketamine (Group K)
Number of subjects: 90